45:1-47 Prescription monitoring program; provisions for expansion.
27.Prescription Monitoring Program; provisions for expansion.
a.Notwithstanding the provisions of section 25 of P.L.2007, c.244 (C.45:1-45) to the contrary, the director may adopt a regulation to expand the program to include information about each prescription dispensed for a prescription drug that is not a controlled dangerous substance. In determining whether a prescription drug other than a controlled dangerous substance should be monitored, the director shall consider: the actual or relative potential for abuse; scientific evidence of its pharmacological effect, if known; the state of current scientific knowledge regarding the drug; its history and current pattern of abuse; the scope, duration and significance of abuse; what, if any, risk to the public health; and its psychic or physiological dependence liability. The regulation shall provide that the prescription drug shall be monitored for a period of time. At the conclusion of the monitoring period, the director shall publish and make public the decision of whether inclusion of the prescription drug in the program shall be permanent.
b.At the time the notice to expand the program pursuant to subsection a. is published in the New Jersey Register, the director shall provide a copy of the notice of proposed rule making to the chairpersons of the standing legislative reference committees on health of the Senate and General Assembly.
L.2007, c.244, s.27.
Section: Previous 45-1-42 45-1-43 45-1-44 45-1-45 45-1-45.1 45-1-46 45-1-46.1 45-1-47 45-1-48 45-1-49 45-1-50 45-1-50.1 45-1-50.2 45-1-51 45-1-52 Next
Last modified: October 11, 2016